Top 10 Oncology Capital Raises in the U.S. – December 1st-15th, 2024

Several interesting transactions closed in the Oncology sector over the past two weeks. If you would like more info on these deals or would like to discuss the capital raising market for your company, please contact me.

PIPE

1. Rakovina Therapeutics, engaged in drug discovery research, preclinical and clinical development, and regulatory affairs necessary to advance breakthrough innovations to become potential life-changing treatments in the oncology field, received CAD 3 million of development capital.
2. Telomir Pharmaceuticals, pioneering preclinical-stage pharmaceutical company leading the advancement of age-reversal science, received $1 million of development capital from Starwood Property Trust.

Buyout/LBO

3. Lumos Pharma, a biopharmaceutical company that develops treatments for cancer and rare diseases. It carries out both clinical-stage and preclinical research on a range of molecules that help the immune system fight off cancer cells, acquired by Double Point Ventures through a $28.02 million LBO.

Merger/Acquisition

4. Cone Health, provider of not-for-profit healthcare network services intended to serve people in Alamance, Forsyth, Guilford, Randolph, Rockingham, and surrounding counties, acquired by Risant Health, a subsidiary of Kaiser Permanente.
5. Integrated Oncology Network, provider of oncology center development, management, advisory services and capital for physician practices and hospitals, acquired by Cardinal Health for $1.12 billion.

Later Stage VC

6. DermaSensor, developer of a skin cancer evaluation technology designed to provide spectroscopy and machine learning technologies to detect skin cancer early, raised $8.93 million through a combination of Series B-2, Series B-3, and Series B-4 venture funding.
7. KisoJi, developer of multi-specific antibodies intended to address targets in oncology and other diseases, raised CAD.41 million of venture funding in a deal led by Investissement Québec and Lumira Ventures.

Early Stage VC

8. OncoVerity, operator of a biotechnology firm intended to develop targeted therapies for cancer, raised $14 million of Series A venture funding in a deal led by Argenx and RefinedScience.

Seed Round

9. Alessa Therapeutics, developer of a drug delivery implantable system designed to treat patients with prostate cancer, raised $15 million of seed funding from Johnson & Johnson and Mission BioCapital.

Accelerator/Incubator

10. Yellowbird Diagnostics, developer of medical imaging agents designed to provide molecular information about inflammation, cancer, or other diseases, joined Capital BioVentures as a part of First Cohort of Ottawa Biotech Accelerator Program.

#castleplacement #capitalraising #privateequity #venturecapital #investment #Oncology

Please contact me if you have any questions or would like to discuss your capital raise:

Email: glevy@castleplacement.com

(C) (516) 457-0104

Send us a message:

Sources: Information on this page was derived from a variety of sources including Bloomberg, Company Websites, Crunchbase, PitchBook and other news outlets. Castle Placement™ does not warrant or guarantee this information, nor makes any representations as to the accuracy of the information. For more Risks, see CPGO Risks and Disclaimers.